Kiniksa Pharmaceuticals International, plc
KNSA
Classificação em ações
#2912
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Preço da ação
$82.00
Valor de mercado
$6.40B
Variação (1 dia)
3.17%
Variação (1 ano)
110.31%
País
GB
Negociar Kiniksa Pharmaceuticals International, plc (KNSA)
Categoria
Healthcare
Lucros da Kiniksa Pharmaceuticals International, plc (KNSA)
Lucros em Jun 2026 TTM: $114.25M
De acordo com os últimos relatórios financeiros da Kiniksa Pharmaceuticals International, plc, os ganhos atuais da empresa são de $114.25M. Em 2023, a empresa teve ganhos de $-16.65M, uma diminuição em relação a aos ganhos de 2022, que foram de $11.03M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Kiniksa Pharmaceuticals International, plc de 2016 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $114.25M | -416.03% |
| 2024 | $-36.15M | 117.10% |
| 2023 | $-16.65M | -251.02% |
| 2022 | $11.03M | -107.04% |
| 2021 | $-156.54M | 0.20% |
| 2020 | $-156.23M | -4.69% |
| 2019 | $-163.91M | 58.46% |
| 2018 | $-103.44M | 59.46% |
| 2017 | $-64.87M | 171.01% |
| 2016 | $-23.94M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $1.35B | 1,081.48% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -76.92% |
US
|
